Loading...

AVBP ARRIVENT BIOPHARMA INC Expansion Plans 8-K Filing

RRVN

VBP

ARRIVENT BIOPHARMA INC

(AVBP)

2025 8-K

Stock Offering Update

Financial Results Released

Presentation Announcement

Financial Results Report

Financial Results Announcement

Data Presentation

Product Expansion

Equity Offerings

Product Expansion

Financial Statements

Accounting Firm Change

Financial Results

License Agreement

Q3 Financial Results

Positive Trial Results

External Links:

On July 21, 2025, ArriVent BioPharma announced that the pivotal phase 3 data for their drug firmonertinib, targeting certain lung cancer mutations, is expected to be available in early 2026.

AI Assistant

ARRIVENT BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.